Le Lézard
Classified in: Health
Subjects: RCL, PSF

Advisory - CanPrev Natural Health Products Ltd. recalls certain lots of Magnesium Bis-Glycinate Powder 250 because of a packaging error


OTTAWA, ON, May 8, 2021 /CNW/ -

Summary

Issue
CanPrev Natural Health Products Ltd. is recalling one lot each of Magnesium Bis-Glycinate Powder 250 (Berry Hibiscus) and Magnesium Bis-Glycinate Powder 250 (Rose Hip Dragonfruit) because they were packaged with a scoop that is nearly twice the size it should be, which may lead users to take nearly twice the intended dose of magnesium.

The products are drink powders promoted for health maintenance, and are indicated for children ages 9 and up, and adults.

The affected lots contain a 20 cc scoop instead of an 11 cc scoop. Using the 20 cc scoop will result in consumers receiving approximately 487 to 498 mg of magnesium instead of the intended daily dose of 250 mg. It also exceeds the upper daily limit for magnesium (not including from food and water), which is 350 mg for ages 9 and up. Magnesium, when taken at doses above 350 mg per day, may cause diarrhea and abdominal cramping.

The products were distributed nationally since December 2020.

Affected products

Product

NPN

Lot

Expiry

Magnesium Bis-Glycinate Powder 250 (Berry Hibiscus)

80097084

MBH001

Sept 2022

Magnesium Bis-Glycinate Powder 250 (Rose Hip Dragonfruit)

80097086

MRD001

Sept 2022

What you should do

Magnesium Bis-Glycinate Powder 250 (Berry Hibiscus) (CNW Group/Health Canada)

Magnesium Bis-Glycinate Powder 250 (Rose Hip Dragonfruit) (CNW Group/Health Canada)

SOURCE Health Canada


These press releases may also interest you

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...

at 07:30
During an awards ceremony to present the 2024 list of Best Workplacestm in Canada, Great Place to Work® announced the 50 Best Workplacestm in Canada with 100-999 employees....

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...



News published on and distributed by: